

BOARD'S REPORT

To,

The Members of

Qmin Pharma Private Limited.

Your Directors have pleasure in presenting their Board Report together with the Audited financial statement and the Auditors' Report of your company for the financial year ended March 31, 2018.

FINANCIAL HIGHLIGHTS

(Amount in Rs.)

<u>Particulars</u>	<u>2017-18</u>	<u>2016-17</u>
Revenue from operation	0	0
Other Income	0	0
Total Income	0	0
Total expenses	3500	2500
Profit Before Interest and Depreciation	(3500)	(2500)
Less: Financial Interest	-	-
Depreciation	0	0
Net Profit/(Loss) Before Tax	(3500)	(2500)
Less: Provision for tax	0	0
Net Profit/(Loss) After Tax	(3500)	(2500)

STATE OF COMPANY'S AFFAIRS AND FUTURE OUTLOOK

During the year the Company has incurred loss of Rs. 3,500/- in comparison to the loss of Previous year of Rs. 2,500/-.

CHANGE IN NATURE OF BUSINESS

Your Company continues to operate in same business segment as that of previous year and there is no change in the nature of the business.

DIVIDEND

In view of the loss incurred during the year, the Board of directors has not recommended any dividend for current year.

TRANSFER TO RESERVES

The Board of Directors has not transferred any amount to the reserves of the Company. All the loss has been transferred to carried forward debit balance of profit and loss account.

INFORMATION ABOUT SUBSIDIARY / JV/ ASSOCIATE COMPANY

The Company has one associate company i.e Vaxtex Cotfab Limited.

MEETINGS OF THE BOARD OF DIRECTORS

During the Financial Year 2017-18, the Company held Four (4) meetings of the Board of Directors as per Section 173 of Companies Act, 2013. The provisions of Companies Act, 2013 were adhered to while considering the time gap between two meetings.

DIRECTORS & KEY MANAGERIAL PERSONNEL

During the year, there was no change in the constitution of the Board of the Company.

COMMITTEE OF BOARD OF DIRECTORS

Your Company does not fall within the criteria as per prescribed under section 135, 177 & 178 of the Companies Act, 2013. Hence Disclosure pertaining to section 135, 177 & 178 are not applicable and provided for the financial year 2017-18.

DEPOSITS

The company has not accepted any deposits during the year. Further there is no outstanding deposit as at the closure of Financial Year 2017-18. Therefore Information relating to deposits, covered under Chapter V of the Act is not applicable to the Company.

SHARE CAPITAL

During the year there was no change in the Share Capital of the Company which is as follows:

1. Authorised Capital

Rs. 1,00,000 /- divided into 10,000 Equity Shares of Rs. 10/- each.

2. Paid Up Capital

Rs. 100,000 /- divided into 10000 Equity Shares of Rs. 10/- each.

LOANS, GUARANTEES AND INVESTMENTS

Details Pertaining to Loans, Guarantees Securities and Investments is provided in the notes to accounts in the Financial Statement.

RELATED PARTY TRANSACTIONS

The Company has not entered into any Related Parties Transactions as defined under Section 188 of the Companies Act, 2013 with related parties as defined under Section 2 (76) of the said Act.

MATERIAL CHANGES AND COMMITMENTS

There are no Material changes and commitments affecting the financial position of the Company which have occurred between the current financial years of the Company and date of approval of Financial Statements.

EXTRACT OF ANNUAL RETURN

The Extract of Annual Return as required under section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014, in Form MGT-9 is annexed herewith as an **Annexure – 1**.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134(5) of the Companies Act, 2013 the Board of Directors of the Company confirms that-

- a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b) The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
- c) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) The directors had prepared the annual accounts on a going concern basis;
- e) Company being unlisted Company, Clause (e) is not applicable; and
- f) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO:

A. Conservation of energy:

- i) Steps taken / impact on conservation of energy:

Your Company is firmly committed to reduce the consumption of power by introducing more energy efficient technology. The operations of the Company are not energy intensive. However the Company endeavored to conserve energy consumption wherever feasible.

- ii) Steps taken by the company for utilizing alternate sources of energy including waste generated:

Nil

- iii) Capital investment on energy conservation equipment:

NIL

B. Technology absorption:

- i) The efforts made towards technology absorption;

No special efforts made towards technology absorption. However, your Company continues its commitment to up the quality by absorbing the latest technology.

- ii) The benefits derived like product improvement, cost reduction, product development or import substitution;

Not Applicable

- iii) In case of imported technology (imported during the last three years reckoned from the beginning of the financial year)-

There is no import of technology during last three years. Hence information as required to be provided under rule 9.8 (3) (B) (iii) of Companies (Accounts) Rules, 2014, are nil.

C. Foreign exchange earnings and Outgo (Amount in Rs.)

There was no foreign earning and outgo during the year under review.

AUDITORS AND REPORT THEREON:

M/s. Niranjani Jain & Co., Chartered Accountants, Ahmedabad, was appointed as Statutory Auditor of the Company for a period of 5 years, subject to ratification of appointment at every subsequent Annual General Meeting. The Company has received the certificate from them to the effect that the appointment if made, would be within prescribed limits under Section 139 of the Companies Act 2013. The Board of Directors recommends their appointment as Statutory Auditor of the Company.

The Auditors' Report on the accounts of the Company for the financial year ended on March 31, 2018 is self-explanatory and do not call for further explanations or comments that may be treated as adequate compliance of Section 134 of the Companies Act, 2013.

GENERAL DISCLOSURES

Your Directors state that the Company has made disclosures in this report for the items prescribed in section 134(3) of the Act and Rule 8 of The Companies [Accounts] Rules, 2014 to the extent the transactions took place on those items during the year.

ACKNOWLEDGEMENT

The Board places on record their appreciation of the support of all stakeholders.

**By the order of the Board,
Qmin Pharma Private Limited**

GUPTA
KHUSHANT

Director

Place : Ahmedabad

Date : September 03, 2018

FORM NO. MGT 9

EXTRACT OF ANNUAL RETURN

As on financial year ended on March 31, 2018

(Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company (Management & Administration) Rules, 2014)

I. REGISTRATION & OTHER DETAILS:

1.	CIN	U51397GJ2009PTC058937
2.	Registration Date	18/12/2009
3.	Name of the Company	Qmin Pharma Private Limited
4.	Category/Sub-category of the Company	Company Limited by Shares / Indian Non-Government Company
5.	Address of the Registered office & contact details	404, Vision Complex, 14, Devang Park Society, Panjra Pole Char Rasta, Ambawadi, Ahmedabad-380015
6.	Whether listed company	No
7.	Name, Address & contact details of the Registrar & Transfer Agent, if any.	N.A.

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY (All the business activities contributing 10 % or more of the total turnover of the company shall be stated)

S. No.	Name and Description of main products / services	NIC Code of the Product/service	% to total turnover of the company

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:- NA**IV. SHARE HOLDING PATTERN****A. Category wise Share Holding**

Category of Shareholders	No. of Shares held at the beginning of the year [As on 31-March-2017]				No. of Shares held at the end of the year [As on 31-March-2018]				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual / HUF	-	10000	10000	100.00	-	10000	10000	100.00	0
b) Central Govt	-	-	-	-	-	-	-	-	-
c) State Govt(s)	-	-	-	-	-	-	-	-	-
d) Bodies Corp.	-	-	-	-	-	-	-	-	-
e) Banks / FI	-	-	-	-	-	-	-	-	-
f) Any other	-	-	-	-	-	-	-	-	-
Total shareholding of Promoter (A)	-	10000	10000	100.00	-	10000	10000	100.00	-

B. Public Shareholding									
1. Institutions	-	-	-	-	-	-	-	-	-
a) Mutual Funds	-	-	-	-	-	-	-	-	-
b) Banks / FI	-	-	-	-	-	-	-	-	-
c) Central Govt	-	-	-	-	-	-	-	-	-
d) State Govt(s)	-	-	-	-	-	-	-	-	-
e) Venture Capital Funds	-	-	-	-	-	-	-	-	-
f) Insurance Companies	-	-	-	-	-	-	-	-	-
g) FIIs	-	-	-	-	-	-	-	-	-
h) Foreign Venture Capital Funds	-	-	-	-	-	-	-	-	-
i) Others (specify)	-	-	-	-	-	-	-	-	-
Sub-total (B)(1):-	-	-	-	-	-	-	-	-	-
2. Non-Institutions									
a) Bodies Corp.	-	-	-	-	-	-	-	-	-
i) Indian	-	-	-	-	-	-	-	-	-
ii) Overseas	-	-	-	-	-	-	-	-	-
b) Individuals	-	-	-	-	-	-	-	-	-
i) Individual shareholders holding nominal share capital upto Rs. 1 lakh	-	-	-	-	-	-	-	-	-
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	-	-	-	-	-	-	-	-	-
c) Others (specify)	-	-	-	-	-	-	-	-	-
Non Resident Indians	-	-	-	-	-	-	-	-	-
Overseas Corporate Bodies	-	-	-	-	-	-	-	-	-
Foreign Nationals	-	-	-	-	-	-	-	-	-
Clearing Members	-	-	-	-	-	-	-	-	-
Trusts	-	-	-	-	-	-	-	-	-
Foreign Bodies - D R	-	-	-	-	-	-	-	-	-
Sub-total (B)(2):-	-	-	-	-	-	-	-	-	-
Total Public Shareholding (B)=(B)(1)+ (B)(2)	-	-	-	-	-	-	-	-	-
C. Shares held by Custodian for GDRs & ADRs	-	-	-	-	-	-	-	-	-
Grand Total (A+B+C)	-	10000	10000	100.00	-	10000	10000	100.00	-

B. Shareholding of Promoter

SN	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in shareholding during the year
		No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	
1	Mr. Khushant Gupta	4900	49.00	-	4900	49.00	-	0.00
2	Mrs. Bharti Gupta	5100	51.00	-	5100	51.00	-	0.00

C. Change in Shareholding of Promoter:

Name	Shareholding of each promoter	Shareholding		CumulativeShareholding during theyear	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
Mr. Khushant Gupta	At the beginning of the year	4900	49.00	4900	49.00
	At the end of the year	4900	49.00	4900	49.00
Mrs. Bharti Gupta	At the beginning of the year	5100	51.00	5100	51.00
	At the end of the year	5100	51.00	5100	51.00

D. Shareholding Pattern of top ten Shareholders: NA

E. Changes in Shareholding Pattern of top ten Shareholders: NA

F. Shareholding of Directors and Key Managerial Personnel:

Name	Shareholding of each Director	Shareholding		CumulativeShareholding during theyear	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
Mr. Khushant Gupta	At the beginning of the year	4900	49.00	4900	49.00
	At the end of the year	4900	49.00	4900	49.00
Mrs. Bharti Gupta	At the beginning of the year	5100	51.00	5100	51.00
	At the end of the year	5100	51.00	5100	51.00

V. INDEBTEDNESS : Nil

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:-

Company has not paid any kind of Remuneration, Salary, Perquisites, Compensation, Sitting Fee(s), and Commission etc. to any Director(s) or KMP.

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES: NO

**By the order of the Board,
Qmin Pharma Private Limited**

GUPTA
KHUSHANT

Digitally signed by GUPTA KHUSHANT
DN: c=IN, o=Personal, cn=GUPTA KHUSHANT,
serialNumber=2a3fc4435abf5b69b8c4b6d08a7c7f5f555,
e=kh2sec613eead5b89c6974bec4, postalCode=380004,
2.5.4.20=11d3fd067a915062d401873bd81140d2658cc
1266462718293705d40753b, st=Gujarat
Date: 2018.12.15 15:30:32.52 +05'30'

Director

Place : Ahmedabad

Date : September 03, 2018

INDEPENDENT AUDITOR'S REPORT
To the Members of QMIN PHARMA PRIVATE LIMITED.

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of QMIN PHARMA PRIVATE LIMITED (hereinafter referred to as "the Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), and its associates comprising of the consolidated Balance Sheet as at 31 March 2018, the consolidated Statement of Profit and Loss including other comprehensive income, the consolidated Cash Flow Statement, the consolidated Statement of Changes in Equity for the year then ended and a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

Management's Responsibility for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation of these consolidated financial statements in terms of the requirement of the Companies Act, 2013 ("the Act") that give a true and fair view of the consolidated financial position, consolidated financial performance including other comprehensive income, consolidated cash flows and consolidated statement of changes in equity of the Group in accordance with accounting principles generally accepted in India. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. While conducting the audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under. We conducted our audit in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Holding Company's preparation of the consolidated financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Holding Company's Board of Directors, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the consolidated state of affairs of the Group as at 31st March 2018, their consolidated profit including other comprehensive income, their consolidated cash flows and consolidated statement of changes in equity for the year ended on that date.

Report on Other Legal and Regulatory Requirements

As required by section 143 (3) of the Act, we report, to the extent applicable, that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the aforesaid consolidated financial statements;
- (b) In our opinion proper books of account as required by law relating to preparation of the aforesaid consolidation of the financial statements have been kept so far as it appears from our examination of those books;
- (c) The consolidated Balance Sheet, consolidated Statement of Profit and Loss including the Statement of Other Comprehensive Income, the consolidated Cash Flow Statement and consolidated Statement of Changes in Equity dealt with by this Report are in agreement with the books of account maintained for the purpose of preparation of the consolidated financial statements;
- (d) In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under section 133 of the Act.
- (e) On the basis of the written representations received from the directors of the Holding Company and subsidiary companies incorporated in India as on 31 March 2018 taken on record by the Board of Directors of the Holding Company and of its subsidiaries respectively, none of the directors of the Group's companies incorporated in India is disqualified as on 31 March 2018 from being appointed as a director in terms of Section 164(2) of the Act.




- (f) With respect to the adequacy and the operating effectiveness of the internal financial controls over financial reporting of the Holding Company and its subsidiary companies, incorporated in India, refer to our separate report in "Annexure I" to this report;
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The consolidated financial statements disclose the impact of pending litigations on its consolidated financial position of the Group – Refer Note 36 and 50 to the consolidated financial statements;
 - ii. Provision has been made in the consolidated financial statements, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts – Refer Note 21 to the consolidated financial statements in respect of such items as it relates to the Group; and
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Holding Company, its subsidiaries, incorporated in India during the year ended 31 March 2018;

Place: Ahmedabad
Date: 03/09/2018



For, Niranjani Jain & Co.
Chartered Accountants
Firm Reg. No. :113913W


Niranjani Jain
Proprietor
Membership No. 047811

Annexure 1 to the Independent Auditor's Report of even date on the consolidated financial statements of QMIN PHARMA PRIVATE LIMITED Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

To the Members of QMIN PHARMA PRIVATE LIMITED.

In conjunction with our audit of the consolidated financial statements of QMIN PHARMA PRIVATE LIMITED, as of and for the year ended 31 March 2018, we have audited the internal financial controls over financial reporting of QMIN PHARMA PRIVATE LIMITED. (hereinafter referred to as the "Holding Company") and its subsidiary companies, which are companies incorporated in India, as of that date.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the of the Holding Company and its subsidiary companies which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, both, issued by Institute of Chartered Accountants of India, and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorization of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Holding Company and its subsidiary companies, which are companies incorporated in India, have, maintained in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2018, based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place: Ahmedabad
Date: 03/09/2018



For, Niranjani Jain & Co.
Chartered Accountants
Firm Reg. No. :113913W

Niranjani Jain
Proprietor
Membership No. 047811

QMIN PHARMA PVT LTD.
Consolidated Balance Sheet as at 31st March 2018

(Amount in Rs.)			
Particulars	Notes No.	Amount as at 31/03/2018	Amount as at 31/03/2017
I. EQUITY AND LIABILITIES			
(1) Shareholders' funds			
(a) Share capital	1	1,00,000	1,00,000
(b) Reserves and surplus	2	25,77,723	18,34,448
(c) Money received against share warrants		-	-
(2) Share application money pending allotment		-	-
(3) Non-current liabilities			
(a) Long-term borrowings	3	1,30,000	1,25,000
(b) Deferred tax liabilities (Net)		-	-
(c) Other Long term liabilities	4	-	-
(d) Long-term provisions	5	-	-
(4) Current liabilities			
(a) Short-term borrowings	6	-	-
(b) Trade payables		-	-
(c) Other current liabilities	7	-	-
(d) Short-term provisions	8	3,500	4,000
Total		28,11,223	20,63,448
II. ASSETS			
(1) Non-current assets			
(a) Fixed assets	9		
(i) Tangible assets		-	-
(ii) Intangible assets		-	-
(iii) Capital work-in-progress		-	-
(iv) Intangible assets under Development		-	-
(b) Non-Current Investments	10	28,09,448	20,62,673
(c) Deferred tax assets (net)		-	-
(d) Long-term loans and advances	11	-	-
(e) Other non-current assets	12	-	-
(2) Current assets			
(a) Current investments	13	-	-
(b) Inventories	14	-	-
(c) Trade receivables	15	-	-
(d) Cash and cash equivalents	16	1,775	775
(e) Short-term loans and advances	17	-	-
(f) Other current assets	18	-	-
Total		28,11,223	20,63,448

As per our report of even date

For, Niranjana Jain & Co
Chartered Accountant
Firm Reg. No. 113913W

(Niranjana Jain)
Proprietor
Membership No. 047811

Place: Ahmedabad
Date: 03/09/2018



For and on behalf of the Board of Directors
QMIN PHARMA PVT LTD.

Director

Director

Place: Ahmedabad
Date: 03/09/2018

QMIN PHARMA PVT LTD.

Consolidated Profit and Loss Statement for the period ended 31st March 2018

(Amount in Rs)

Particulars	Notes No.	Amount as at 31/03/2018	Amount as at 31/03/2017
I. Revenue from operations	19	-	-
II. Other income	20	-	-
III. Total Revenue (I+II)		-	-
IV. Expenses			
Cost of Material Consumed	21	-	-
Purchase of Stock-in-Trade		-	-
Change in Inventories of....		-	-
Employee Benefit Expenses	22	-	-
Finance Cost	23	-	-
Depreciation and Amortization Expenses	9	-	-
Other Expense	24	3,500	2,500
Total Expenses		3,500	2,500
V. Profit before Exceptional and extraordinary expenses and tax (III-IV)		(3,500)	(2,500)
VI. Exceptional Expenses		-	-
VII. Profit before Extraordinary expenses and tax (V-VI)		(3,500)	(2,500)
VIII. Extraordinary Activities		-	-
IX. Profit Before Tax (VII-VIII)		(3,500)	(2,500)
X. Tax Expense			
Current Tax		-	-
Deferred Tax		-	-
XI. Profit (Loss) for the period from continuing operations (VII-VIII)		(3,500)	(2,500)
XII. Profit / Loss from Discountinuing Operations		-	-
XIII. Tax Expense on Discountinuing Operations		-	-
XIV. Profit / Loss from Discountinuing Operations (After Tax) (-	-
XV. Profit or Loss For the Period (XI+XIV)		(3,500)	(2,500)
XVI. Earning per Equity Share			
Basic			
Diluted			

As per our report of even date.

For, Niranjani Jain & Co
Chartered Accountant

Firm Reg. No. : 113913W

(Niranjani Jain)
Proprietor

Membership No. 047811

Place : Ahmedabad

Date : 03/09/2018



For and on behalf of Board of Directors
QMIN PHARMA PVT LTD.

Director

Director

Place : Ahmedabad

Date : 03/09/2018

QMIN PHARMA PVT LTD.

Notes to Consolidated Financial Statements for the Year Ended 31st March 2018

1. Share Capital	As at 31/03/2017		As at 31/03/2016	
	No. of Shares	Rs.	No. of Shares	Rs.
Authorized Capital				
10,000 Equity shares of rs.10 each	10,000	1,00,000	10,000	1,00,000
Issued and Subscribed				
10,000 Equity shares of rs.10 each	10,000	1,00,000	10,000	1,00,000
Subscribed and Fully Paid				
10,000 Equity shares of rs.10 each	10,000	1,00,000	10,000	1,00,000
	-	-	-	-
Total	10,000	1,00,000	10,000	1,00,000

1.1 Particulars of Shares holders holding more than 5% of the Shares Capital:

Name of Shareholder	No. of Shares	% of Holding
BHARTI K GUPTA	5100	51%
KHUSHANT V GUPTA	4900	49%
Total	10000	100%

1.2 Reconciliation of the shares outstanding at the beginning and at the end of the reporting period:

Particulars	Opening Balance	Issue	Buy Back	Closing Balance
Equity shares				
Year ended 31st March, 2018				
- Number of shares	10000	0	0	10000
- Amount (Rs)	100000	0	0	100000
Year ended 31st March, 2017				
- Number of shares	10000	0	0	10000
- Amount (Rs)	100000	0	0	100000

1.3 The Company has only one class of shares referred to as equity shares with a face value of 10 per share. Each holder is entitled to one vote per share.

1.4 Fully paid up equity shares issued pursuant to contract(s) without payment Being received in cash in the last five years

Nil

1.5 Fully paid up equity shares by way of bonus shares in the last five years

Nil

1.6 Shares bought back in the five years

Nil



QMIN PHARMA PVT LTD.

Notes to Consolidated Financial Statements for the Year Ended 31st March 2018

2. Reserve & Surplus	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Capital Reserve	16,79,735	17,72,592
(b) Secutirites Premium	-	-
(c) Profit & Loss A/c		
Balance as Per Last Financial Statements	61,856	(28,500)
Profit/(Loss) For the Year	(3,500)	(2,500)
Addition During the Year	839632	92,856
Less : Adjustments		
Closing Balance of Profit & Loss A/c	8,97,988	61,856
Total	25,77,723	18,34,448

3. Long Term Borrowings	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Debentures and Bonds	-	-
(b) Term Loan		
(i) From banks	-	-
(ii) From Others	-	-
(c) Unsecured Loan from Others	1,30,000	1,25,000
(d) Deposits	-	-
(e) Loan and Advances From Related Parties	-	-
(f) Long Term Maturities of Finance Lease Obligations	-	-
Total	1,30,000	1,25,000

4. Other Long Term Liabilities	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Trade Payables	-	-
(b) Others	-	-
Total	-	-

5. Long Term Provisions	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Provision for Employees Benefits	-	-
(b) Others	-	-
Total	-	-



6. Short Term Borrowings	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Loans Repayable on Demand		
(i) From Banks	-	-
(ii) From Other Parties	-	-
(b) Loans and Advances from Related Parties	-	-
(c) Deposits	-	-
(d) Other Loans and Advances	-	-
Total	-	-

7. Other Current Liabilities	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Current Maturities of Long Term Debt	-	-
(b) Current Maturities of Finance Lease Obligations	-	-
(c) Interest Accrued but not Due on Borrowings	-	-
(d) Interest Accrued and Due on Borrowings	-	-
(e) Income Received in Advance	-	-
(f) Unpaid Dividends	-	-
(g) Other Payables	-	-
Total	-	-

8. Short Term Provisions	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Provision for Employees Benefits	-	-
(b) Others		
Unpaid Accounting fee		
Provision for Audit Fees	2,000	1,000
Provision for Expenses	1,500	3,000
Unpaid Salary		-
Total	3,500	4,000



QMIN PHARMA PVT LTD.

Notes to Consolidated Financial Statements for the Year Ended 31st March 2018

10. Non-Current Investments	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Trade Investments	-	-
(b) Long Term Investments	1,97,225	1,97,225
(c) Investment Associate Company	2612223	1865448
Total	28,09,448	20,62,673

11. Long Term Loans and Advances	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Capital Advances	-	-
(b) Security Deposits	-	-
(c) loans and Advances to Related Party	-	-
(d) Other Loans and Advances	-	-
Total	-	-

12. Other Non-Current Assets	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Long Term Trade Recievables		
(i) Secured, Considered good	-	-
(ii) Unsecured, Condidered good	-	-
(iii) Doubtful	-	-
(b) Others	-	-
Total	-	-

13. Current Investments	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Investments in Equity Instruments	-	-
(b) Investment in Government Securities	-	-
(b) Investment in Debentures or Bonds	-	-
(b) Investment in Mutual Funds	-	-
(b) Investment in Partnership Firms	-	-
(b) Other Investment	-	-
Total	-	-



14. Inventories	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Raw Materials	-	-
(b) Work-in-Progress	-	-
(b) Finished Goods	-	-
(b) Stock in trade	-	-
(b) Stores & Spares	-	-
(b) Loose Tools	-	-
Total	-	-

15. Trade Receivables	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Due for More than Six Months	-	-
(b) Others	-	-
Total	-	-

16. Cash and Cash Equivalents	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Balance with Banks	-	-
<u>Balance in Current Account with Co operative Bank</u> The Kalupur co-operative Bank		
(b) Cheques, Drafts on hand	-	
(b) Cash on Hand	1,775	775
Total	1,775	775

17. Short Term Loans and Advances	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) loans and Advances to Related Party	-	-
(b) <u>Other Loans and Advances</u>		
Other Loans		
Balance with Revenue Authority :		
Advance Income Tax		
Income Tax		
TDS Receivable		
Total	-	-

18. Other Current Assets	Amount as at 31/03/2017	Amount as at 31/03/2016
	-	-
	-	-
Total	-	-



QMIN PHARMA PVT LTD.

Notes to Consolidated Financial Statements for the Year Ended 31st March 2018

19. Revenue from operations	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Sale of Products	-	-
(b) Sale of Services	-	-
(c) other Operating Revenue	-	-
Less: Excises Duty	-	-
Total	-	-

20. Other Income	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Interest Income	-	-
(b) Dividend income	-	-
(c) Net gain / (loss) on Sale of investments	-	-
(d) Other Non Operating revenues	-	-
Total	-	-

21. Cost of Material Consumed	Amount as at 31/03/2018	Amount as at 31/03/2017
<u>Raw Material</u>	-	-
Opening Stock	-	-
Add: Purchase	-	-
Less: Closing Stock	-	-
Total	-	-

22. Employee Benefit Cost	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Salaries and Wages	-	-
(b) Contribution to Provident and Other Funds	-	-
(c) Remuneration to Directors	-	-
(d) Expenses on ESPO & ESPP	-	-
(e) Staff Welfare Expenses	-	-
Total	-	-

23. Finance Cost	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Interest Expense	-	-
(b) Other Borrowing Cost	-	-
(c) Applicable net Gain / (Loss) on Foreign Currency Transaction and Translations	-	-
(d) Others	-	-
Bank Charges	-	-
Total	-	-

24. Other Expense	Amount as at 31/03/2018	Amount as at 31/03/2017
<u>Administrative exps and other exps</u>		
Auditor's Remuneration		
As Auditor	2,000	1,000
Legal & Professional Charges	1,500	1,500
TOTAL(a)	3,500	2,500
Total(a+b+c+d)	3,500	2,500



QMIN PHARMA PVT LTD.

Notes to Consolidated Financial Statements for the Year Ended 31st March 2018

9. Fixed Assets and Depreciation & Amortization

Sr. No	Particulars	Cost	Gross Block			Depreciation			Net Block	
			Value at the beginning	Addition during the year	Deletion during the year	Value at the end	Value at the beginning	Addition during the year	Deletion during the year	Value at the end
I	<u>Intangible Assets</u>									
	SUB TOTAL (A)									
II	<u>Intangible Assets</u>									
III	<u>Capital Work-in-progress</u>									
	Building Under Construction									
	SUB TOTAL (B)									
IV	<u>Intangible Assets Under Development</u>									
	SUB TOTAL (C)									
	SUB TOTAL (D)									
	Total (A + B + C + D) (Current Year)									
	(Previous Year)									



INDEPENDENT AUDITOR'S REPORT

To,
The Members of QMIN PHARMA PVT. LTD.

Report on the Financial Statements

Opinion:

We have audited the accompanying financial statements of QMIN PHARMA PVT. LTD. ("the Company"), which comprise the Balance Sheet as at 31/03/2018, the Statement of Profit and Loss, the cash flow statement for the year then ended, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- (a) in the case of the Balance Sheet, of the state of affairs of the Company as at March 31, 2018 and,
- (b) in the case of the Profit and Loss Account, of the profit / loss for the year ended on that date.

Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibility of the Management for the Standalone Financial Statements:


The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, (changes in equity)[iv] and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process

Auditor's Responsibility:

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.




Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditors' Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub section (11) of section 143 of the Companies Act, 2013.


As required by Section 143 (3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- (b). In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c). The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- (d). In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e). On the basis of the written representations received from the directors as on 31st March, 2018 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2018 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f). With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements.
 - ii. The Company did not have any long term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

Place: Ahmedabad
Date: 03/09/2018



For, Niranjani Jain & Co.
Chartered Accountants
Firm Reg. No. :113913W


Niranjani Jain
Proprietor
Membership No. 047811

QMIN PHARMA PVT LTD.
Balance Sheet as at 31st March 2018

(Amount in Rs.)


Particulars	Notes No.	Amount as at 31/03/2018	Amount as at 31/03/2017
I. EQUITY AND LIABILITIES			
(1) Shareholders' funds			
(a) Share capital	1	1,00,000	1,00,000
(b) Reserves and surplus	2	(34,500)	(31,000)
(c) Money received against share warrants		-	-
(2) Share application money pending allotment		-	-
(3) Non-current liabilities			
(a) Long-term borrowings	3	1,30,000	1,25,000
(b) Deferred tax liabilities (Net)		-	-
(c) Other Long term liabilities	4	-	-
(d) Long-term provisions	5	-	-
(4) Current liabilities			
(a) Short-term borrowings	6	-	-
(b) Trade payables		-	-
(c) Other current liabilities	7	-	-
(d) Short-term provisions	8	3,500	4,000
Total		1,99,000	1,98,000
II. ASSETS			
(1) Non-current assets			
(a) Fixed assets	9		
(i) Tangible assets			-
(ii) Intangible assets			
(iii) Capital work-in-progress			
(iv) Intangible assets under Development			
(b) Non-Current Investments	10	1,97,225	1,97,225
(c) Deferred tax assets (net)		-	-
(d) Long-term loans and advances	11	-	-
(e) Other non-current assets	12	-	-
(2) Current assets			
(a) Current investments	13	-	-
(b) Inventories	14	-	-
(c) Trade receivables	15	-	-
(d) Cash and cash equivalents	16	1,775	775
(e) Short-term loans and advances	17	-	-
(f) Other current assets	18	-	-
Total		1,99,000	1,98,000

As per our report of even date.

For, Niranjn Jain & Co
Chartered Accountant
Firm Reg. No. : 113913VV



(Niranjn Jain)
Proprietor
Membership No. 047811



For and on behalf of the Board of Directors
QMIN PHARMA PVT LTD.

Director

Director

Place : Ahmedabad
Date : 03/09/2018

Place : Ahmedabad
Date : 03/09/2018

QMIN PHARMA PVT LTD.
Profit and Loss Statement for the period ended 31st March 2018


(Amount in Rs)

Particulars	Notes No.	Amount as at 31/03/2018	Amount as at 31/03/2017
I. Revenue from operations	19	-	-
II. Other income	20	-	-
III. Total Revenue (I+II)		-	-
IV. Expenses			
Cost of Material Consumed	21	-	-
Purchase of Stock-in-Trade		-	-
Change in Inventories of....		-	-
Employee Benefit Expenses	22	-	-
Finance Cost	23	-	-
Depreciation and Amortization Expenses	9	-	-
Other Expense	24	3,500	2,500
Total Expenses		3,500	2,500
V. Profit before Exceptional and extraordinary expenses and tax (III-IV)		(3,500)	(2,500)
VI. Exceptional Expenses		-	-
VII. Profit before Extraordinary expenses and tax (V-VI)		(3,500)	(2,500)
VIII. Extraordinary Activities		-	-
IX. Profit Before Tax (VII-VIII)		(3,500)	(2,500)
X. Tax Expense			
Current Tax		-	-
Deferred Tax		-	-
XI. Profit (Loss) for the period from continuing operations (VII-VIII)		(3,500)	(2,500)
XII. Profit / Loss from Discountinuing Operations		-	-
XIII. Tax Expense on Discountinuing Operations		-	-
XIV. Profit / Loss from Discountinuing Operations (After Tax) (-	-
XV. Profit or Loss For the Period (XI+XIV)		(3,500)	(2,500)
XVI. Earning per Equity Share			
Basic			
Diluted			


As per our report of even date.

For, Niranjn Jain & Co
Chartered Accountant

Firm Reg. No. : 113913W


(Niranjn Jain)
Proprietor

Membership No. 047811



Place : Ahmedabad

Date : 03/09/2018

For and on behalf of Board of Directors
QMIN PHARMA PVT LTD.

Director

Director

Place : Ahmedabad

Date : 03/09/2018

QMIN PHARMA PVT LTD.

Notes to Financial Statements for the Year Ended 31st March 2018

1. Share Capital	As at 31/03/2017		As at 31/03/2016	
	No. of Shares	Rs.	No. of Shares	Rs.
Authorized Capital				
10,000 Equity shares of rs.10 each	10,000	1,00,000	10,000	1,00,000
Issued and Subscribed				
10,000 Equity shares of rs.10 each	10,000	1,00,000	10,000	1,00,000
Subscribed and Fully Paid				
10,000 Equity shares of rs.10 each	10,000	1,00,000	10,000	1,00,000
	-	-	-	-
Total	10,000	1,00,000	10,000	1,00,000

1.1 Particulars of Shares holders holding more than 5% of the Shares Capital:

Name of Shareholder	No. of Shares	% of Holding
BHARTI K GUPTA	5100	51%
KHUSHANT V GUPTA	4900	49%
Total	10000	100%

1.2 Reconciliation of the shares outstanding at the beginning and at the end of the reporting period:

Particulars	Opening Balance	Issue	Buy Back	Closing Balance
Equity shares				
Year ended 31st March, 2018				
- Number of shares	10000	0	0	10000
- Amount (Rs)	100000	0	0	100000
Year ended 31st March, 2017				
- Number of shares	10000	0	0	10000
- Amount (Rs)	100000	0	0	100000

1.3 The Company has only one class of shares referred to as equity shares with a face value of 10 per share. Each holder is entitled to one vote per share.

1.4 Fully paid up equity shares issued pursuant to contract(s) without payment

Being received in cash in the last five years

Nil

1.5 Fully paid up equity shares by way of bonus shares in the last five years

Nil

1.6 Shares bought back in the five years

Nil



QMIN PHARMA PVT LTD.

Notes to Financial Statements for the Year Ended 31st March 2018

2. Reserve & Surplus	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Capital Reserve	-	-
(b) Secutirites Premium	-	-
(c) Profit & Loss A/c		
Balance as Per Last Financial Statements	(31,000)	(28,500)
Profit/(Loss) For the Year	(3,500)	(2,500)
Addition During the Year	-	-
Less : Adjustments	-	-
Closing Balance of Profit & Loss A/c	(34,500)	(31,000)
Total	(34,500)	(31,000)

3. Long Term Borrowings	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Debentures and Bonds	-	-
(b) Term Loan		
(i) From banks	-	-
(ii) From Others	-	-
(c) Unsecured Loan from Others	1,30,000	1,25,000
(d) Deposits	-	-
(e) Loan and Advances From Related Parties	-	-
(f) Long Term Maturities of Finance Lease Obligations	-	-
Total	1,30,000	1,25,000

4. Other Long Term Liabilities	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Trade Payables	-	-
(b) Others	-	-
Total	-	-

5. Long Term Provisions	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Provision for Employees Benefits	-	-
(b) Others	-	-
Total	-	-



6. Short Term Borrowings	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Loans Repayable on Demand		
(i) From Banks	-	-
(ii) From Other Parties	-	-
(b) Loans and Advances from Relate	-	-
(c) Deposits	-	-
(d) Other Loans and Advances	-	-
Total	-	-

7. Other Current Liabilities	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Current Maturities of Long Term Debt	-	-
(b) Current Maturities of Finance Lease Obligations	-	-
(c) Interest Accrued but not Due on Borrowings	-	-
(d) Interest Accrued and Due on Borrowings	-	-
(e) Income Received in Advance	-	-
(f) Unpaid Dividends	-	-
(g) Other Payables	-	-
Total	-	-

8. Short Term Provisions	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Provision for Employees Benefits	-	-
(b) Others		
Unpaid Accounting fee		
Provision for Audit Fees	2,000	1,000
Provision for Expenses	1,500	3,000
Unpaid Salary		-
Total	3,500	4,000



QMIN PHARMA PVT LTD.

Notes to Financial Statements for the Year Ended 31st March 2018

9. Fixed Assets and Depreciation & Amortization

Sr. No	Particulars	Rate %	Gross Block			Depreciation			Net Block	
			Value at the beginning	Addition during the year	Deduction during the year	Value at the end	Value at the beginning	Addition during the year	Deduction during the year	Value at the end
I	Tangible Assets									
	1 Office equipment									
	2 Furniture									
	3 Plot									
	SUB TOTAL (A)		-	-	-	-	-	-	-	-
II	Intangible Assets									
	SUB TOTAL (B)		-	-	-	-	-	-	-	-
III	Capital Work-in-progress									
	1 Building Under Construction									
	SUB TOTAL (C)		-	-	-	-	-	-	-	-
IV	Intangible Assets Under Development									
	SUB TOTAL (D)		-	-	-	-	-	-	-	-
	Total [A + B + C + D]	(Current Year)	-	-	-	-	-	-	-	-
		(Previous Year)	-	-	-	-	-	-	-	-



QMIN PHARMA PVT LTD.

Notes to Financial Statements for the Year Ended 31st March 2018

10. Non-Current Investments	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Trade Investments	-	-
(b) Other Investments	1,97,225	1,97,225
Total	1,97,225	1,97,225

11. Long Term Loans and Advances	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Capital Advances	-	-
(b) Security Deposits	-	-
(c) loans and Advances to Related Party	-	-
(d) Other Loans and Advances	-	-
Total	-	-

12. Other Non-Current Assets	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Long Term Trade Recievables		
(i) Secured, Considered good	-	-
(ii) Unsecured, Condidered good	-	-
(iii) Doubtful	-	-
(b) Others	-	-
Total	-	-

13. Current Investments	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Investments in Equity Instruments	-	-
(b) Investment in Government Securities	-	-
(b) Investment in Debentures or Bonds	-	-
(b) Investment in Mutual Funds	-	-
(b) Investment in Partnership Firms	-	-
(b) Other Investment	-	-
Total	-	-



14. Inventories	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Raw Materials	-	-
(b) Work-in-Progress	-	-
(b) Finished Goods	-	-
(b) Stock in trade	-	-
(b) Stores & Spares	-	-
(b) Loose Tools	-	-
Total	-	-

15. Trade Receivables	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Due for More than Six Months	-	-
(b) Others	-	-
Total	-	-

16. Cash and Cash Equivalents	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Balance with Banks	-	-
<u>Balance in Current Account with Co operative Bank</u> The Kalupur co-operative Bank	-	-
(b) Cheques, Drafts on hand	-	-
(b) Cash on Hand	1,775	775
Total	1,775	775

17. Short Term Loans and Advances	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) loans and Advances to Related Party	-	-
(b) Other Loans and Advances	-	-
Other Loans	-	-
<u>Balance with Revenue Authority :</u> Advance Income Tax Income Tax TDS Receivable	-	-
Total	-	-

18. Other Current Assets	Amount as at 31/03/2017	Amount as at 31/03/2016
	-	-
Total	-	-



QMIN PHARMA PVT LTD.

Notes to Financial Statements for the Year Ended 31st March 2018

19. Revenue from operations	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Sale of Products	-	-
(b) Sale of Services	-	-
(c) other Operating Revenue	-	-
Less: Excise Duty	-	-
Total	-	-


20. Other Income	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Interest Income	-	-
(b) Dividend income	-	-
(c) Net gain / (loss) on Sale of Investments	-	-
(d) Other Non Operating revenues	-	-
Total	-	-

21. Cost of Material Consumed	Amount as at 31/03/2018	Amount as at 31/03/2017
Raw Material	-	-
Opening Stock	-	-
Add: Purchase	-	-
Less: Closing Stock	-	-
Total	-	-

22. Employee Benefit Cost	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Salaries and Wages	-	-
(b) Contribution to Provident and Other Funds	-	-
(c) Remuneration to Directors	-	-
(c) Expenses on ESPO & ESPP	-	-
(d) Staff Welfare Expenses	-	-
Total	-	-

23. Finance Cost	Amount as at 31/03/2018	Amount as at 31/03/2017
(a) Interest Expense	-	-
(b) Other Borrowing Cost	-	-
(c) Applicable net Gain / (Loss) on Foreign Currency Transaction and Translations	-	-
(d) Others	-	-
Bank Charges	-	-
Total	-	-

24. Other Expense	Amount as at 31/03/2018	Amount as at 31/03/2017
Administrative exps and other exps		
Auditor's Remuneration		
As Auditor	2,000	1,000
Legal & Professional Charges	1,500	1,500
TOTAL(a)	3,500	2,500
Total(a+b+c+d)	3,500	2,500



Note No-1

SIGNIFICANT ACCOUNTING POLICIES & NOTES FORMING PART OF ACCOUNT AS ON 31ST MARCH 2018

1. Accounting Policies:-

a. Basis of Accounting:-

The financial statement are prepared under the historical cost convention on the accrual basis accounting in accordance with the provisions of the Companies Act, 2013 and Generally Accepted Accounting Principles in India and the Companies (Accounts) Rules, 2014 as amended from time to time to the extent applicable.

b. Revenue Recognition:-

Revenue is primarily derived from sale of Goods; the revenue is recognized when goods sold are dispatched to customers. Sales include Excise Duty and Sales Tax, VAT, CST and net of rebate, rate difference and sales return.

c. Investment:-

Investment is valued at cost.

d. Fixed Assets:-

Fixed Assets are stated at cost of acquisition\construction. Cost of fixed assets includes Tax, where credit is not taken. Duties, freight, and other incidental expenses related to acquisition and construction. Interest on borrowed to finance acquisition of fixed assets during the construction period has been capitalized.

e. Depreciation:-

The Company has provided depreciation on Fixed Assets based on useful life of the assets as prescribed in Schedule II of Companies Act, 2013.

f. Taxation:-

The company has made adequate provision of current taxes and deferred tax as per AS 22 of the ICAI and provisions for both has been accounted in financial statement.

g. Employee Benefits:-

(a) Short term employee's benefits are recognized as an expense at the undiscounted amount in the Profit and Loss account for the year in which related services rendered by the employees to the company.

(b) The company has long term defined benefit plans of which the company has not been obtained the actuarial valuation. However, these benefits are provided in financial statement on payment basis.



1. Sundry Debtors, Creditors, Loans and Advances are subject to their confirmation and hence, subject to adjustment, if any, arising out of reconciliation.
2. Previous year figures have been rearranged/regrouped, wherever necessary to make them comparable with current year figures.
3. In the opinion of the Board, the Current Assets, Loans and Advances are stated at the values, which are realizable in the ordinary course of the business, and provision for all known liabilities has been made.
4. Figures have been rounded off to the nearest rupee.
5. Wherever the necessary evidences / supporting are not available in respect of the transactions accounted, they have been approved by the management.

For, Niranjana Jain & Co.
Chartered Accountants
Firm Reg. No. :113913W



Niranjan Jain
Proprietor

Membership No. 047811